Patient-tailored training programme on cardiorespiratory fitness, trunk strength and mobility leads to significantly better outcomes in individuals with axial spondyloarthritis Authors: Sophie De Mits, Tine Willems, Patrick Calders, Lieven Danneels, Gaëlle Varkas, Filip Van den Bosch, Dirk Elewaut, Philippe Carron Published: 2025 ABSTRACT AbstractBackgroundAxial spondyloarthritis (axSpA) impairs trunk strength, mobility and cardiorespiratory fitness. Despite exercise being a key treatment, few studies have examined a combined trunk mobility, strength and cardiorespiratory training programme. This prospective interventional study assessed the benefits of a personalised training programme based on baseline physical tests.MethodsPeople with axSpA underwent cardiopulmonary exercise testing (CPET) and trunk strength/mobility assessments using the David Back Concept (DBC) devices. Strength and mobility deficits were calculated, and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Metrology Index (BASMI) and chest expansion (CE) were recorded pre-intervention and post-intervention. The 8-week programme included two sessions per week of cardiorespiratory training (based on ventilatory threshold, heart rate monitored via a Polar device), followed by resistance/mobility exercises on DBC devices. Training intensity was tailored to each individual’s one-repetition-maximum and range of motion at baseline. Post-intervention, CPET and DBC tests were repeated. Changes were analysed using linear mixed models.Results30 individuals with axSpA (14 males/16 females, age 42±11.2 years, BASDAI 3.5±2.1, BASFI 2.8±2.2, BASMI 2.0±1.1, CE 4.5±2.0 cm) participated; two were lost to follow-up. Strength increased by 14.1% (p<0.001) and mobility by 14.9% (p<0.001). Significant improvements occurred in oxygen pulse (p=0.004), ventilatory efficiency (p<0.001), anaerobic threshold (p=0.002) and mechanical efficiency (p=0.021). BASDAI (2.9±2.2, p=0.021) and CE (5.0±2.1, p=0.020) improved significantly; BASMI (1.8±1.0, p=0.053) showed borderline improvement, while BASFI remained unchanged (2.4±2.1, p=0.092).ConclusionA combined, tailored and baseline-guided training programme significantly enhanced cardiorespiratory fitness, trunk strength and trunk mobility in individuals with axSpA, supporting individualised exercise interventions to improve outcomes and reduce functional limitations.Keywords: Axial Spondyloarthritis, Rehabilitation, Physical Therapy Modalities WHAT IS ALREADY KNOWN ON THIS TOPIC Exercise therapy is an important and crucial pillar in the non-pharmacological treatment of axial spondyloarthritis (axSpA). Exercise therapy is an important and crucial pillar in the non-pharmacological treatment of axial spondyloarthritis (axSpA). Several types of exercise have shown a beneficial effect on both mobility and strength as well as on cardiopulmonary fitness. Several types of exercise have shown a beneficial effect on both mobility and strength as well as on cardiopulmonary fitness. WHAT THIS STUDY ADDS A combined, tailored and baseline-guided training programme significantly enhanced cardiorespiratory fitness, trunk strength and trunk mobility in individuals with axSpA. A combined, tailored and baseline-guided training programme significantly enhanced cardiorespiratory fitness, trunk strength and trunk mobility in individuals with axSpA. A personalised training programme, based on objective individual measurements of trunk mobility and strength and a maximal cardiopulmonary exercise test, and targeting the typical affected areas, can address individual needs and limitations of people with axSpA. A personalised training programme, based on objective individual measurements of trunk mobility and strength and a maximal cardiopulmonary exercise test, and targeting the typical affected areas, can address individual needs and limitations of people with axSpA. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY This study contributes to adjusting the content of general exercise recommendations for people with axSpA. This study contributes to adjusting the content of general exercise recommendations for people with axSpA. This training programme targets the specific areas most affected by axSpA, such as the trunk strength and mobility, and can be used as a framework for future studies. This training programme targets the specific areas most affected by axSpA, such as the trunk strength and mobility, and can be used as a framework for future studies. Introduction Axial spondyloarthritis (axSpA) is an inflammatory rheumatic condition clinically characterised by inflammatory back pain and loss of spine and/or chest mobility as the most prominent symptoms.1 Furthermore, individuals with (ax)SpA have been shown to be more susceptible to cardiovascular2 and pulmonary3 comorbidities. Consequently, both restricted mobility and diminished cardiopulmonary fitness compromise the quality of life of people with axSpA.1 3 Physical activity (PA) and exercise therapy are the cornerstones of treatment.1 4 5 PA is defined as any bodily movement produced by skeletal muscles that results in energy expenditure above resting levels, whereas exercise is considered a planned, structured and repetitive subset of PA aimed at improving or maintaining physical fitness.6 Recent reviews and meta-analyses have documented the effects of various exercise programmes on different domains such as pain, disease activity and function in people with axSpA. Although the exercise modalities were highly heterogeneous—including strengthening and flexibility training, Tai chi, Pilates, global postural education, aquatic exercises, etc—they all proved to have a positive effect on muscle strength, pain, disease activity, the Bath Ankylosing Spondylitis Metrology Index (BASMI), the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), the Bath Ankylosing Spondylitis Functional Index (BASFI), quality of life and overall functioning.7,16 Despite the positive effects, it should be noted that most of the strengthening programmes focus on peripheral muscle strength and not on trunk strength, which is a key factor in axSpA. Beyond the benefits on disease activity and function, exercise also contributes to reducing cardiovascular risk, improving respiratory function and preventing osteoporosis in both healthy individuals and in patients with chronic diseases such as type 2 diabetes, chronic obstructive pulmonary disease and heart failure.1017,19 However, in axSpA, these outcomes have been studied far less extensively and show conflicting results. Some studies could not demonstrate a significant improvement, while others documented an improvement in cardiorespiratory fitness.1216 20,24 These discrepancies may be attributed to variations in sample size and heterogeneity of the included patients. Furthermore, it has been suggested that rehabilitation may enhance the effectiveness of tumour necrosis factor-inhibitor therapy25 26 and that these exercise interventions are well tolerated without leading to serious adverse events.12 Nevertheless, there remains a lack of consensus regarding the optimal exercise programme for individuals with axSpA. The necessity of a well-defined framework outlining the specific type, dose, frequency and duration of training programmes has not yet been adequately addressed. Current guidelines recommend offering a patient-tailored programme, based on general recommendations, without specifying the content or advising on adaptations for individuals with axSpA.1 5 Therefore, the present study aimed to investigate the effects of a training programme not only on trunk strength and spinal mobility but also on cardiorespiratory fitness in individuals with axSpA. A unique aspect of this study is that baseline data were used to tailor the personalised training programme, targeting multiple aforementioned outcomes. Methods Study population Patients between 18 and 70 years old were recruited by their treating rheumatologist from the outpatient clinic at Ghent University Hospital. All participants met the current ASsessment of Ankylosing Spondylitis classification criteria for axSpA. Exclusion criteria included pregnancy, acute flare (defined as a sudden worsening of pain and/or inflammation), cardiovascular disease, chronic obstructive pulmonary disease, trauma or surgery within the 6 months prior to baseline, or other coexisting diseases interfering with the ability to perform the testing and training programme. For strength and mobility measures, healthy control data, provided by the David Back Concept (DBC) company (age-matched and gender-matched Finnish population), were used as the reference population. In contrast, physiological parameters were compared with normative data for healthy adults. For clinical cardiopulmonary exercise testing (CPET) interpretation, cut-off values were used to evaluate normality.27,32 Procedure The following self-administered questionnaires were completed by the participants at baseline: the Tampa Scale for Kinesiophobia (TSK)33 and the modified Short QUestionnaire to ASsess Health enhancing physical activity (mSQUASH).34 The TSK assesses fear of movement, while the mSQUASH inventories the daily PA. The BASDAI and the BASFI were assessed at baseline and post-intervention. Both BASDAI and BASFI are specific disease-related standardised questionnaires, evaluating disease activity and function status, respectively. Likewise, the BASMI (cervical rotation, lumbar flexion, lumbar lateral flexion, intermalleolar distance and tragus to wall distance) as well as chest expansion (CE) were measured at baseline and post-intervention. The following test procedures were performed at baseline and after completion of the training programme. To measure maximal mobility and isometric strength of the trunk, while minimising compensation strategies, DBC devices (https://davidhealth.com/products/) were used. Previous studies have reported that DBC device results are valid and reliable.35,37 For mobility assessments, the objective was moving as far as possible within the standardised position on the device. The equipment ensured isolated trunk movement without compensation strategies. Maximal isometric flexion, extension, lateral flexion and rotation strength measurements were performed on the dedicated DBC devices. Participants were instructed to inhale before starting the test and exhale during performance. The target curve, displayed on the device, required reaching maximal contraction within 2 s and holding it for an additional 3 s. Positioning during assessment was standardised at an angle of 30° (left and right lateral flexion, flexion for extension strength and left and right rotation in frontal, sagittal and transversal planes, respectively), except for trunk flexion strength, which was measured in a neutral position (0°). Each strength measurement was performed two times, and if a difference of more than 10% in maximum strength was observed between attempts, a third assessment was conducted. The average of the attempts was used for further analysis. Exercise tolerance was measured using cycle ergospirometry, which included direct pulmonary measurements of oxygen consumption (VO2), carbon dioxide production (VCO2) and ventilation (VE) and was monitored by a 12-lead ECG. The test was preceded by a 30 s resting ECG, reviewed by a physician. To ensure participant safety, an alarm was set at 85% of the predicted maximal heart rate (HRmaxpred). A ramp protocol was used, starting with a 2 min warm-up of easy cycling at 25 Watts, followed by an increase of 25 Watts per minute until exhaustion. Participants were instructed to maintain a cadence of 65–75 rotations per minute (rpm) and to report perceived exertion using the Borg scale. The test was terminated if any of the following criteria were met: exceeding 85% of HRmaxpred, Borg scale rating ≥17, cadence <60 rpm or reporting symptoms such as feeling unwell, dizziness or muscle cramps. Based on the first ventilatory threshold (VT1), VO2, VCO2 and HR and the peak (peak) and predicted (pred) values, different derived parameters were calculated: respiratory condition (PeakVO2/VO2pred), oxygen pulse (VO2/HR), ventilatory efficiency (VE/VCO2), mechanical efficiency ((T2VE − T1VE) / (T2VCO2 − T1VCO2)) and the anaerobic threshold (VO2VT1/predpeakVO2). For data analysis, trunk strength and mobility in individuals with axSpA were compared with an age-matched and sex-matched Finnish reference population embedded in the DBC software package. The primary outcome variables were mobility and strength deficits, calculated using the formula ‘Deficit = (Reference value – Patient value) x100/Reference value’. The higher the patient’s deficit, the greater the impairment compared with a healthy reference subject. Aerobic capacity was compared with predicted normative values.28 29 31 38 The exercise intervention consisted of an 8 weeks training programme with two sessions per week. Each session contained two blocks of 10 min of aerobic training and three sets of exercises on the four DBC devices. Details about the training programme are provided in the Consensus on Exercise Reporting Template (CERT) chart in the online supplemental material. For the aerobic component, participants could choose from various cardiovascular equipment, including a bicycle, treadmill, cross trainer or rowing machine. Each session comprised two blocks of warm-up and 10 min of training within a predetermined HR zone. During the first 4 weeks, participants trained within an HR zone defined as 100%±10 beats based on VT1. In the subsequent 4 weeks, intensity increased to 10% above HR at VT1 (±10 beats). HR was monitored using a Polar device. The exercises on the four DBC devices targeted trunk mobility and strength. Exercises were progressively intensified by adjusting either the percentage of the one-repetition maximum (1RM) by varying from 30% to 55% of the 1RM and by varying repetitions between 3×10 and 3×17 reps across different range of motion (ROM) limits. Throughout the intervention, supervision and assistance were provided to ensure correct execution, safety and effectiveness. Statistics Linear mixed models were used to examine the effect of the intervention over time (IBM SPSS Statistics, V.29). Two models were built for mobility and strength deficits, respectively, including the main effects of time and direction (flexion, extension, lateral flexion and rotation), the interaction between time and direction and a random intercept. Additionally, the effect of time was tested on respiratory condition, oxygen pulse, ventilatory efficiency, mechanical efficiency, anaerobic threshold, BASMI, BASDAI, BASFI and CE. Interaction effects between gender, age, mSQUASH, TSK and time were examined and included if significant. Results 30 participants (47% males, 42±11.2 years) were included. All participants exhibited stable disease activity and were on a stable pharmacological regimen. Baseline characteristics are presented in table 1. Table 1Participants characteristics of included individuals with patients with axSpA at baselineNumber of participants (%)Male14 (47)r-axSpA(11) 37Current medication use NSAID22 (73.3) csDMARDs5 (16.7) bDMARDs18 (60.0) Corticosteroids1 (3.3)Smoking Never20 (66.7) Stop >3 years6 (20.0) Currently4 (13.3)Alcohol use Never3 (10.0) <3 units/day25 (83.3) ≥3 units/day2 (6.7)Mean (SD)RangeAge, yr42.3 (11.2)21–67Height, cm173.3 (8.1)157–188Weight, kg75.0 (12.1)56–100Symptom duration, yr17.5 (13.5)1–61BASMI2.02 (1.1)0.51–4.74Chest expansion, cm4.6 (1.9)1–9BASDAI (0–10)3.5 (2.1)0.4–7.1BASFI (0–10)2.7 (2.2)0–7.2TSK39.1 (5.8)28–49mSQUASH9205.6 (4126.1)1425–17850b, biological; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; cs, conventional synthetic; DMARD, disease modifying anti-rheumatic drugs; mSQUASH, modified Short QUestionnaire to ASsess Health enhancing physical activity; NSAID, non-steroidal anti-inflammatory drugs; r-axSpA, radiographic axial spondyloarthritis; TSK, Tampa Scale for Kinesiophobia; yr, year. Participants characteristics of included individuals with patients with axSpA at baseline b, biological; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; cs, conventional synthetic; DMARD, disease modifying anti-rheumatic drugs; mSQUASH, modified Short QUestionnaire to ASsess Health enhancing physical activity; NSAID, non-steroidal anti-inflammatory drugs; r-axSpA, radiographic axial spondyloarthritis; TSK, Tampa Scale for Kinesiophobia; yr, year. The mean score for the TSK was 39.13 (range 28–49), with 16 (53.3%) participants scoring above the threshold of 37, indicating kinesiophobia. The activity score measured by the mSQUASH questionnaire ranged from 1425 to 17 850 with an average of 9205; higher mSQUASH scores are indicative of a higher PA level. Two participants were lost to follow-up due to flare and personal reasons. A significant positive effect of the intervention was observed on strength deficit across all measured directions (p<0.001). The strength deficit decreased on average by 14.10% (95% CI 8.86% to 19.33%) after the training programme (see table 2 and figure 1A). For mobility, the interaction between time and direction, as well as the main effects of time and direction, was all significant (p<0.001). A mean decrease in mobility deficit of 14.88% (95% CI 10.37% to 19.40%) was observed after the training programme. The decrease in lateral flexion deficit was the highest (approximately 27.2%) and was significantly greater compared with the changes in flexion (p=0.042), extension (p<0.001) and rotation (p<0.001). The decrease in rotation deficit was the second highest (approximately 22.4%). The flexion deficit decreased by approximately 10.4%, while there was no effect on extension deficit after the training programme (see table 2 and figure 1B). For neither strength nor mobility, an additional interaction effect of gender, age, mSQUASH or TSK could be determined. Table 2Mobility and strength deficits descriptivesMobility deficits (°)Strength deficits (Nm)PrePostPrePostMeanSDMeanSDMeanSDMeanSDLumbar/thoracic extension9.922.611.328.820.230.87.128.5Lumbar/thoracic flexion7.519.3−1.98.119.923.614.223.0Lumbar/thoracic rotation right15.721.9−5.117.218.130.11.329.4Lumbar/thoracic rotation left19.819.8−0.916.014.730.30.637.7Lumbar/thoracic lateral flexion right10.826.8−14.225.031.034.011.034.8Lumbar/thoracic lateral flexion left7.926.0−19.424.829.034.58.535.8Post, post-intervention; Pre, pre-intervention. Mobility and strength deficits descriptives Post, post-intervention; Pre, pre-intervention. Mean strength (A) and mobility (B) deficits before and after the intervention programme for the different directions. Deficit = (reference value – patient value) × 100 / reference value. A significant improvement was observed after the training programme in oxygen pulse (p=0.004), ventilatory efficiency (p<0.001), anaerobic threshold (p=0.002) and mechanical efficiency (p=0.021). No additional effects of gender, age, mSQUASH or TSK were identified during the analysis of these cardiorespiratory parameters. A significant effect of time on respiratory condition was only observed when mSQUASH was taken into account. After the training programme, there was a significant increase in respiratory condition (p=0.003); however, this increase was significantly lower for those with higher mSQUASH scores (interaction effect: p=0.008). The increase in respiratory condition after the training programme decreased by 0.003 (95% CI 0.001 to 0.006) for 1-unit increase in mSQUASH. Mean and SDs for cardiorespiratory parameters before and after the training programme are shown in table 3. Table 3Cardiorespiratory parameters before and after the training programmePrePostEstimated time effectP valueMeanSDMeanSDMean95% CIAnaerobic threshold, % (VO2VT1/VO2pred)58.117.772.221.613.815.40 to 22.230.002Oxygen pulse, % (VO2/HR)12.93.514.43.41.390.48 to 2.310.004Ventilatory efficiency (VE/VCO2)24.72.526.42.51.650.82 to 2.47<0.001Respiratory condition, % (PeakVO2/VO2pred)94.822.210325.78.37−2.63 to 19.360.13Mechanical efficiency (T2VE − T1VE) / (T2VCO2 − T1VCO2)25.93.525.513.61.090.18 to 2.000.021HR, heartrate; pred, predicted; T1, time point 1; T2, time point 2; VCO2, carbon dioxide production; VE, ventilation; VO2, oxygen consumption; VT1, first ventilatory threshold. Cardiorespiratory parameters before and after the training programme HR, heartrate; pred, predicted; T1, time point 1; T2, time point 2; VCO2, carbon dioxide production; VE, ventilation; VO2, oxygen consumption; VT1, first ventilatory threshold. The BASDAI score significantly decreased after the training programme (p=0.021). A trend towards a decrease was observed for the BASMI (p=0.053), while no significant differences were noted for the BASFI (p=0.092). There was a significant interaction effect of age and time (p=0.050) in addition to the main effect of time (p=0.020), when analysing the effect on CE. An average increase of 0.6 cm was observed post-test; however, this increase diminished with age (−0.06 cm (95% CI – 0.11 to 0) per year increase). Mean and SDs for axSpA functional parameters before and after the training programme are shown in table 4. Table 4clinical parameters before and after interventionPrePostEstimated time effectP valueMeanSDMeanSDMean95% CIBASFI score2.82.22.42.1−0.448−0.974 to 0.0790.092BASDAI score3.52.12.92.2−0.579−1.066 to −0.0920.021Total BASMI score2.01.11.81.0−0.285−0.574 to 0.0040.053Chest expansion4.51.952.10.586−0.060 to 1.2310.073BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index. clinical parameters before and after intervention BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index. Discussion This study represents the outcomes of an 8-week patient-tailored training programme in people with axSpA, contributing to the currently limited and heterogeneous literature in this field. The results indicate a significant improvement in both trunk strength and mobility as well as in cardiorespiratory fitness, following the application of a personalised training programme based on objective baseline measurements. The novelty of this study lies in the combination of objective trunk strength and mobility measurements with a maximal CPET, as well as the use of objective baseline parameters to tailor the training programme to the individual patient. Moreover, the intervention was designed to facilitate a progressive adaptation to the training programme, acknowledging individual variations in fitness levels at baseline. This approach allowed participants to gradually increase the intensity of both aerobic and resistance exercises over the 8-week period, ensuring a safe and personalised training experience. Our results are promising, especially considering the simplicity and short duration of the 8-week intervention. Our findings are consistent with previous research demonstrating improvements in both physical fitness and pulmonary function parameters,16 20 21 23 as well as with studies reporting enhanced muscle strength39 40 and favourable changes in clinical parameters such as BASMI, BASDAI and BASFI.7,1641 However, previous research on muscle strength in axSpA has not been exclusively focused on or restricted to the trunk musculature, neither in the exercise interventions nor in the assessment protocols. Nonetheless, trunk strength appears to be more compromised than trunk mobility, even though strength is not routinely assessed during clinical follow-up of axSpA, unlike mobility.42 Surprisingly, only a limited number of studies have reported objective measurements of trunk strength. These studies are hampered by the use of diverse measurement methods, such as handheld dynamometers,43 44 endurance protocols45 46 or isokinetic devices,47 which complicate data comparison. To our knowledge, only two small studies used isometric measurements,39 48 comparable to those applied in the current study and in our previous study.42 Both reported reduced trunk strength in individuals with axSpA compared with healthy individuals, as did we. Despite this, standardisation of the training device was implemented solely by Kozakcioglu, including only three individuals with axSpA.39 In this context, our intervention used DBC devices for all included participants, which is a clear strength permitting generalisability across the entire patient population. An additional advantage of using DBC devices is the focus on exercises to the trunk musculature, minimising compensation by other muscle groups. Since the training programme on DBC devices is based on each patient’s 1RM and maximal ROM, it follows a standardised schedule but is tailored to individual capabilities. Although the intervention only spanned 8 weeks, the increase in strength was significant. Regular resistance training enhances maximum strength development through adaptations at the neuromuscular level. Since neural adaptations occur earlier than morphological ones, this increase is most likely due to agonist muscle activation, commonly observed during the first weeks of training and reflected in increased motor unit recruitment and firing frequency. Likewise, a decrease in antagonists activation is seen, contributing to adjust synergists activation timing and degree, resulting in better global intermuscular coordination.49 50 For healthy previously untrained adults, the American College of Sports Medicine recommends initiating with a load of 45–50% of 1RM.50 As recommended, the load within our intervention varied between 30% and 55% of 1RM, providing a safety buffer for participants. However, to achieve larger effect sizes, training at a higher percentage of 1RM would eventually be necessary. Morphological changes, which appear later than neural adaptations, lead to muscle fibre hypertrophy and increased cross-sectional area, requiring progressive overload.49 50 Future interventions should focus on longer intervention periods while increasing the load up to 70–80% of 1RM. As for the changes in mobility, extension deficit did not differ significantly despite the intervention, which may be related to several factors. We found substantial heterogeneity for this parameter at baseline which could be explained by the fact that extension shows the smallest ROM and highest SD of all measurements, with an average ROM of 26°, while flexion, rotation and lateral flexion ROM were on average 47°, 45° and 41°, respectively. From a clinical standpoint, it is reasonable to suggest that, in this specific patient population, extension mobility—and thus extension limitation—is less modifiable due to structural articular restrictions and is therefore unlikely to improve substantially through therapeutic intervention. Regarding CE, the increase after the intervention was age-specific, with older participants showing less improvement compared with younger ones. Not unexpectedly, older patients presented more often with longer disease duration, reflected in respectively additional degenerative changes and possible disease-related structural damage, affecting CE capacity. Likewise, in older patients, the sternocostal and costovertebral joints may be more affected, negatively impacting CE. Ageing also affects soft tissues such as tendons and ligaments, which may limit mobility. For the BASMI, only a trend (p=0.053) towards significant improvement was observed. Measurements were always performed by the same researcher to minimise measurement error. Pre-intervention and post-intervention measurements were scheduled, as much as feasible, at the same time of day for each patient, allowing sufficient time after morning stiffness to avoid its influence on mobility. In general, cardiopulmonary parameters improved after the intervention, except for respiratory condition. Only when mSQUASH—where higher values indicate higher PA—was considered, a significant effect of time on respiratory condition was observed. As expected, the increase was significantly lower for those with higher mSQUASH scores. The cardiorespiratory training programme was based on baseline fitness level, with training HR determined from pretest HR at VT1. Although the programme consisted of two 10 min blocks, it was individualised to each patient’s health status and monitored during training. The choice between different training devices offered flexibility, enhancing motivation and HR monitoring appeared to encourage the participants. Lastly, aside from delayed onset muscle soreness, no adverse events were reported. In our intervention, only two participants dropped out, neither due to inability or unwillingness to continue the programme itself, which underscores the feasibility of our training programme. The limitations of our study include the small sample size, short intervention period and lack of a control group. Additionally, a positive bias cannot be excluded as only motivated individuals, who believe in the therapeutic value of exercise therapy, agreed to participate. Nevertheless, this reflects the reality of applying exercise in a real-world setting, where intrinsic motivation is key to success. Future research should focus on larger cohorts, greater homogeneity and longer intervention periods and/or follow-up, which would shed light on long-term effects and the necessity of maintaining PA. Additionally, the frequency of the intervention should be explored further. Ultimately, practical guidelines should be drafted based on high-quality research in this area, providing clinicians with tools in their therapeutic armamentarium and leading to a more standardised approach to physiotherapy intervention—particularly exercise therapy—in individuals with axSpA. Supplementary material Acknowledgements We thank all the participants for their commitment. Footnotes Funding: The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors. Provenance and peer review: Not commissioned; externally peer reviewed. Patient consent for publication: Not applicable. Ethics approval: This study involves human participants and was approved by Ghent University Hospital Ethical Committee, ONZ-2022-0383. Participants gave informed consent to participate in the study before taking part. Data availability free text: Data will be available upon reasonable request. Data availability statement Data are available upon reasonable request. References Associated Data Supplementary Materials Data Availability Statement Data are available upon reasonable request.